Significance of anti-cyclic citrullinated peptide autoantibodies in immune-mediated inflammatory skin disorders with and without arthritis

Indian Journal of Dermatology

Volumn 61, Issue 5, 2016, Pages 510-514

  Grover, Chander ^a   Kashyap, Bineeta ^a   Daulatabad, Deepashree ^a   Dhawan, Amit ^a   Kaur, Iqbal ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Anti cyclic citrullinated peptide antibodies; C reactive protein; immune mediated; rheumatoid arthritis factor; skin

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTHRITIS; ARTICLE; CHILD; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PSORIASIS; PSORIATIC ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EID: 84987788930     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.190122     Document Type: Article

References (14)

1. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.
2. Artlett CM. Immunology of systemic sclerosis. Front Biosci 2005;10:1707-19.
3. Cunha PR, Barraviera SR. Autoimmune bullous dermatoses. An Bras Dermatol 2009;84:111-24.
4. Kashyap B, Tiwari U, Garg A, Kaur IR. Diagnostic utility of anti-CCP antibodies and rheumatoid factor as inflammatory biomarkers in comparison with C-reactive protein and TNF- in rheumatoid arthritis. Trop J Med Res 2015;18:5-9.
5. Wright V, Moll JM. Psoriatic arthritis. In: Wright V, Moll JM, editors. Seronegative Polyarthritis. Amsterdam: North Holland Publishing Co.; 1976. p. 169-223.
6. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-7.
7. Cimmino MA. Epidemiology of psoriasis and psoriatic arthritis. Reumatismo 2007;59 Suppl 1:19-24.
8. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85.
9. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308.
10. Schmeiser T, Pons-Kühnemann J, Özden F, Müller-Ladner U, Dinser R. Arthritis in patients with systemic sclerosis. Eur J Intern Med 2012;23:e25-9.
11. Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007;26:17-23.
12. Pasquetti P, Morozzi G, Galeazzi M. Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology (Oxford) 2009;48:315-6.
13. Böckelmann R, Gollnick H, Bonnekoh B. Anti-cyclic citrullinated peptide antibodies in psoriasis patients without arthritis. Arthritis Rheum 2006;54:1701-2.
14. Popescu C, Zofota S, Bojinca V, Ionescu R. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus. Rom J Intern Med 2013;51:179-87.